Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Says U.S. FDA To Delay Approval Of Replacement Diabetes Drug

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical said U.S. FDA has delayed review of alogliptin until the Japanese drug maker can supply more data about the diabetes drug. The delay was seen as a blow to Takeda, which faces a 2011 patent expiration on its best-seller Actos (pioglitazone) for treating Type 2 diabetes. Takeda submitted data about the drug candidate at the end of 2007, but FDA said the information did not meet new standards adopted by the agency last year. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts